KRAS and neoplasm: As a clonal KRAS G12C and subclonal KRAS G12V have been previously described in one early-stage NSCLC tumour in the TRACERx study23, we next aimed to assess possible evolution of the mutational events in the six G12C & G12V double-positive cases by investigating the G12C and G12V variant allele frequencies (VAFs).